Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
Revenue for the fourth quarter and full year 2024 was $47.5 million and $179.0 million, respectively. The MRD business, which contributed 85% of revenue in the fourth quarter and 81% of revenue in the ...
New Research Uncovers Hidden Rules of Immune Response, Opening Doors for Better Vaccines and Immunotherapies
Immunotherapies Scientists at the Institute for Systems Biology (ISB) reveal how T cells "decide" their fate in fighting ...
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating ...